Rallybio to Present at the 3rd Annual Evercore ISI HealthCONx Conference

NEW HAVEN, Conn., November 24, 2020 – Rallybio, a clinical-stage biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that Martin Mackay, Chief Executive Officer, Jeff Fryer, Chief Financial Officer and Steve Uden, Chief Operating Officer, will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Virtual Conference on Wednesday, December 2, 2020 at 4:20 p.m. Eastern Time.

A live webcast of the event will be accessible on Rallybio’s website, www.rallybio.com, under the “Investor” section. An archived version of the remarks will also be available through the Company’s website for 90 days following the conference.

About Rallybio

Rallybio is a clinical-stage biopharmaceutical company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, and metabolism. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.